

3-[6-(3,4-dichlorophenyl)-5-methylpyrimidin-4-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one,
 4-(3,4-dichlorophenyl)-5-fluoro-6-(2H-1,2,3,4-tetrazol-5-yl)pyrimidine,
 3-[6-(3,4-dichlorophenyl)-5-fluoropyrimidin-4-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one,
 4-(3,4-dichlorophenyl)-5-methoxy-6-(2H-1,2,3,4-tetrazol-5-yl)pyrimidine,
 3-[6-(3,4-dichlorophenyl)-5-methoxypyrimidin-4-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one,
 5-{7,8-dichloro-6H-isochromeno[4,3-d]pyrimidin-4-yl}-2H-1,2,3,4-tetrazole,
 3-{7,8-dichloro-6H-isochromeno[4,3-d]pyrimidin-4-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one,
 4-(3,4-dichlorophenyl)-6-(2H-1,2,3,4-tetrazol-5-yl)pyrimidin-5-amine,
 3-[5-amino-6-(3,4-dichlorophenyl)pyrimidin-4-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one,
 4-(3,4-dichlorophenyl)-5-(methoxymethyl)-6-(2H-1,2,3,4-tetrazol-5-yl)pyrimidine,
 3-[6-(3,4-dichlorophenyl)-5-(methoxymethyl)pyrimidin-4-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one,
 4-(3-chloro-4-cyclopropoxyphenyl)-6-(2H-1,2,3,4-tetrazol-5-yl)pyrimidin-5-ol,
 3-[6-(3-chloro-4-cyclopropoxyphenyl)-5-hydroxypyrimidin-4-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one,
 4-(3,4-dichlorophenyl)-6-(2H-1,2,3,4-tetrazol-5-yl)pyrimidin-5-ol, and
 3-[6-(3,4-dichlorophenyl)-5-hydroxypyrimidin-4-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one,
 and pharmaceutically acceptable salts and prodrugs thereof.

27. A pharmaceutical composition comprising at least one chemical entity of any one of claims 1 to 26 and at least one pharmaceutically acceptable excipient.

28. Use of at least one chemical entity of any one of claims 1 to 26 in the manufacture of a medicament for A method of treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of at least one chemical entity of any one of claims 1 to 26.

29. The ~~method~~ use of claim 28 wherein at least one chemical entity binds Kynurenine 3-mono-oxygenase.

30. The ~~method~~ use of claim 29 wherein said condition or disorder involves a neurodegenerative pathology.

31. The ~~method~~use of claim 30 wherein the neurodegenerative pathology is selected from Huntington's disease, Alzheimer's disease, Parkinson's disease, olivoponto cerebellar atrophy, non-Alzheimer's dementia, multi-infarctual dementia, cerebral amyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia, spinal or head trauma and epilepsy.

32. A packaged pharmaceutical composition comprising at least one pharmaceutical composition according claim 27 and instructions for using the composition to treat a subject suffering from a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity.

33. The packaged pharmaceutical composition according to claim 32, wherein the condition or disorder is Huntington's disease.